Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


José-Antonio Monge-Argilés has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Validation of Plasma p-tau217 as a Biomarker of Prodromal Alzheimer’s Disease

    by Victoria Monge-García, Sofía Lorenzo-García, María-Carmen Bernal-Soriano, Patricia Torrella-Esteban, Sonia Monge-García, José Sánchez-Payá, José-Antonio Monge-Argilés

    Background:Plasma phosphorylated tau 217 protein (p-tau217p) has recently been proposed as a useful biomarker for the early diagnosis of Alzheimer’s disease (AD). However, local validation is recommended because of the potential influence of clinical, analytical, and preanalytical factors on assay performance.Methods:Between 2021 and 2024, we evaluated patients with amnestic mild cognitive impairment (aMCI) through clinical history, neurological and neuropsychological examination, blood sampling for biobanking, brain imaging, and lumbar puncture, among other diagnostic tests. In September 2025, p-tau217p levels were measured simultaneously using the LUMIPULSE immunoassay (Fujirebio). The diagnostic validity, reproducibility, receiver operating characteristic (ROC) curve performance, correlation with cerebrospinal fluid (CSF) biomarkers, and influence of clinical and analytical variables were evaluated in this study.Results:Among the 108 aMCI patients included, 66 met the criteria for clinic-biological AD, while the remainder had alternative clinical diagnoses. Using a two-threshold approach, p-tau217p levels ≥0.19 yielded a sensitivity of 88% and a positive predictive value of 83% for identifying AD. Levels ≥0.39 showed a specificity of 91% and a positive predictive value of 90% for the same purpose. Intermediate values (0.20–0.38) achieved a specificity of 83%. The intraclass correlation coefficient for the assay reproducibility was 0.97. The ROC curve for p-tau217p demonstrated an area under the curve of 0.86 for diagnosing AD. P-tau217p correlated more strongly with CSF p-tau181 (ρ = 0.63; p < 0.01) than with CSF Aβ1-42 (ρ = –0.40; p < 0.01). Finally, a reduced glomerular filtration rate was associated with a significant increase in p-tau217p levels (p < 0.006).Conclusions:In our setting, p-tau217p measurement showed a high validity for the diagnosis of prodromal AD, which is consistent with the recent neurological literature. The assay showed high reproducibility, although results may be influenced by renal function. P-tau217p correlated more strongly with CSF p-tau181 than with CSF Aβ1-42.

  • Open Access

    Elevated CSF Serotonin in Prodromal Alzheimer’s Disease Patients Developing Psychosis

    by Victoria Monge-García, Rocío Pérez-González, Sonia Monge-García, Ruth Gasparini-Berenguer, José Sánchez-Payá, Raissa de Fátima Silva-Afonso, José-Antonio Monge-Argilés

    Introduction: Psychotic symptoms (PS) in Alzheimer’s disease (AD) are associated with unfavorable prognosis, including accelerated functional decline and reduced survival. Multiple neurotransmitter systems have been implicated in the pathophysiology of PS, with the serotonergic system emerging as particularly relevant. Materials and Methods: Between 2010 and 2020, 120 patients with prodromal AD and 26 cognitively healthy controls underwent comprehensive evaluation, including clinical history, neurological and neuropsychological assessment, neuroimaging, and lumbar puncture. All participants underwent longitudinal clinical monitoring for a minimum of five years or until the emergence of PS. In February 2024, baseline cerebrospinal fluid (CSF) serotonin (5-HT) concentrations were quantified using competitive ELISA (FineTest, Wuhan, China). Results: CSF 5-HT levels were significantly elevated (p < 0.003) in patients who subsequently developed psychosis (n = 49) compared with those who remained free of PS during the 8-year follow-up (n = 19). A threshold of 4.89 ng/mL yielded 80% sensitivity for identifying individuals at risk. Baseline Neuropsychiatric Inventory (NPI; p < 0.001) and Unified Parkinson’s Disease Rating Scale part III (UPDRS III; p < 0.009) scores also demonstrated strong discriminative capacity. Conclusions: Measurement of CSF 5-HT and detailed clinical profiling in prodromal AD may provide predictive value for psychosis onset within 8 years of diagnosis. To our knowledge, this is the first study to report CSF 5-HT findings in AD patients.

  • Open Access

    Validity of CSF alpha-synuclein to predict psychosis in prodromal Alzheimer's disease

    by Sonia Monge-García, María-Salud García-Ayllón, José Sánchez-Payá, Ruth Gasparini-Berenguer, María-Ángeles Cortés-Gómez, Javier Sáez-Valero, José-Antonio Monge-Argilés

    Background: Alzheimer's disease (AD) accompanied by psychotic symptoms (PS) has a poor prognosis and may be associated with imbalances in key neural proteins such as alpha-synuclein (AS).Aim: The aim of the study was to evaluate the diagnostic validity of AS levels in the cerebrospinal fluid (CSF) as a predictor of the emergence of PS in patients with prodromal AD.Materials and methods: Patients with mild cognitive impairment were recruited between 2010 and 2018. Core AD biomarkers and AS levels were measured in CSF obtained during the prodromal phase of the illness. All patients who met the NIA-AA 2018 criteria for AD biomarkers received treatment with anticholinesterasic drugs. Follow-up evaluations were conducted to assess patients for the presence of psychosis using current criteria; the use of neuroleptic drugs was required for inclusion in the psychosis group. Several comparisons were made, taking into account the timing of the emergence of PS.Results: A total of 130 patients with prodromal AD were included in this study. Of these, 50 (38.4%) met the criteria for PS within an 8-year follow-up period. AS was found to be a valuable CSF biomarker to differentiate between the psychotic and non-psychotic groups in every comparison made, depending on the onset of PS. Using an AS level of 1,257 pg/mL as the cutoff, this predictor achieved at least 80% sensitivity.Conclusion: To our knowledge, this study represents the first time that a CSF biomarker has shown diagnostic validity for prediction of the emergence of PS in patients with prodromal AD.


  • Open Access

    Relation between Alpha-Synuclein and Core CSF Biomarkers of Alzheimer’s Disease

    by Victoria Monge-García, María-Salud García-Ayllón, Javier Sáez-Valero, José Sánchez-Payá, Francisco Navarrete-Rueda, Jorge Manzanares-Robles, Ruth Gasparini-Berenguer, Raquel Romero-Lorenzo, María Angeles Cortés-Gómez, José-Antonio Monge-Argilés

    Background: Alzheimer’s disease (AD) is characterized by the presence of β-amyloid plaques and neurofibrillary tangles, while Lewy body dementia (LBD) is characterized by α-synuclein (α-syn) inclusions. Some authors examine α-syn protein in the neurodegeneration process of AD and propose to consider cerebrospinal fluid (CSF) α-syn as a possible additional biomarker to the so-called “core” of AD. Objective: To determine whether there is a correlation between α-syn levels and “core” AD biomarkers in patients with mild cognitive impairment (MCI). Materials and methods: In total, 81 patients in the early stages of MCI were selected from the outpatient dementia consultation in Alicante General Hospital. Using a cross-sectional case–control design, patients were analyzed in four groups: stable MCI (MCIs; n = 25), MCI due to AD (MCI-AD; n = 32), MCI due to LBD (MCI-LBD; n = 24) and a control group of patients with acute or chronic headache (Ctrl; n = 18). Correlation between CSF protein levels in the different groups was assessed by the Rho Spearman test. Results: We found positive correlations between T-tau protein and α-syn (ρ = 0.418; p value < 0.05) and p-tau181p and α-syn (ρ = 0.571; p value < 0.05) exclusively in the MCI-AD group. Conclusion: The correlation found between α-syn and tau proteins in the first stages of AD support the involvement of α-syn in the pathogenesis of AD. This result may have clinical and diagnostic implications, as well as help to apply the new concept of “precision medicine” in patients with MCI.


  • Aportación del cociente Aß1-42/Aß1-40 al concepto ‘enfermedad de Alzheimer contribuye al deterioro cognitivo leve’

    by Victoria Monge García, L. Llorca Tolón, Ruth Gasparini Berenguer, José Antonio Monge Argilés

    Introduction. Evidence of cerebral amyloidosis, by altered levels of the peptide A beta(1-42) or the A beta(1-42)/A beta(1-40) ratio, is a necessary condition to accept the presence of Alzheimer's disease (AD), according to the 2018 criteria of the National Institute on Aging and Alzheimer's Association (NIA-AA 2018). Aim. To calculate the diagnostic gain obtained from calculating the A beta(1-42)/A beta(1-40) ratio with respect to the exclusive use of the peptide A beta(42) to identify patients belonging to the 'Alzheimer's disease contributes to mild cognitive impairment (MCI)' group, according to NIA-AA 2018 criteria. Patients and methods. Between April 2018 and April 2020, we included 62 patients with MCI, according to Petersen's 2006 criteria, who underwent lumbar puncture as part of the diagnostic process. Cerebrospinal fluid was analysed using the immunochemiluminescence methodology, which makes it possible to quantify core AD biomarkers in cerebrospinal fluid and the peptide A beta(1-40). Results. Forty-two patients (67.7%) presented criteria supporting 'AD contributes to MCI'. The use of the A beta(1-42)/A beta(1-40) ratio, compared to the exclusive use of A beta(1-42) levels, represents a diagnostic gain of 19% (eight patients) to establish the presence of amyloidosis in the cerebrospinal fluid of these patients. Conclusion. The calculation of the A beta(1-42)/A beta(1-40) ratio is a clear diagnostic gain for identifying patients belonging to the 'AD contributes to MCI' group, and we therefore recommend its use, as reported in the most recent literature. To our knowledge, this is the first publication of its kind in Spanish.

  • Measurement of CSF α‐synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer’s disease

    by José Antonio Monge‐Argilés, María‐Salud García‐Ayllón, Victoria Monge García, Francisco Navarrete Rueda, Jorge Manzanares Robles, Ruth Gasparini‐Berenguer, Carlos Leiva‐Santana, Javier Sáez‐Valero

    Background: Previous studies have indicated the potential of cerebrospinal fluid (CSF) α‐synuclein (α‐syn) to be an additional biomarker for improving differential diagnosis of Alzheimer’s disease (AD). We evaluated α‐syn diagnostic performance across a well‐characterized patient cohort with long‐term follow‐up.Method: CSF α‐syn levels were determined in 25 subjects diagnosed with stable mild cognitive impairment (stable MCI; n= 25), 27 MCI cases due to AD (MCI‐AD; n= 32), 24 MCI cases due to Lewy body disease (MCI‐LBD; n= 24) and control subjects (Ctrl; n= 18). Levels of central core AD‐CSF biomarkers Aβ1‐42, T‐tau and P‐tau 181 were measured using enzyme‐linked immunosorbant assay (Innotest, Innogenetics/Fujirebio). Determination of α‐syn levels in CSF were performed using the LEGEND MAXTM human α‐synuclein ELISA kit (BioLegend).Result: CSF α‐syn levels discriminate between the four groups. There were higher α‐syn levels in MCI‐AD patients and lower levels in MCI‐LBD patients. The combination of P‐tau and α‐syn resulted in a specificity of 99% and a sensitivity of 97% for AD. MCI‐AD patients with early psychotic symptoms (n= 9) displayed a trend towards a decrease in P‐tau and α‐syn compared to the MCI‐AD patients without psychotic symptoms (n= 23).Conclusion: Adding CSF α‐syn to central core AD biomarkers improves an early differential diagnosis of MCI‐AD from other forms of MCI.

  • Relation between alpha‐synuclein and core CSF biomarkers in Alzheimer's disease

    by José Antonio Monge‐Argilés, María‐Salud García‐Ayllón, Victoria Monge García, Francisco Navarrete Rueda, Jorge Manzanares Robles, Ruth Gasparini‐Berenguer, Carlos Leiva‐Santana, Raquel Romero‐Lorenzo, Javier Sáez‐Valero

    Background: Up to 50% of Alzheimer´s disease (AD) cases exhibit significant Lewy bodies (LB) pathology in addition to plaques and tangles. It has been hypothesized that Aβ, tau and alpha‐synuclein (α‐syn) proteins promote the accumulation of one another. We evaluated the relation between those CSF proteins in a well‐characterized patient mild cognitive impairment (MCI) cohort.Method: Between 2010‐2015, we included 81 MCI patients (Petersen criteria 2006) from the out‐patient consultation of Neurology Service in University General Hospital of Alicante and 18 control subjects. After a long term follow‐up (mean: 53 months), 25 patients were diagnosed with stable MCI, 32 MCI due to AD (MCI‐AD) and 24 MCI due to Lewy body dementia (MCI‐LBD). Levels of central core AD‐CSF biomarkers Aβ1‐42 (Aβ42), T‐tau (total‐tau) and P‐tau [phospho‐tau (181P)] were measured using ELISA (Innotest, Innogenetics/Fujirebio). Determination of α‐syn levels in CSF were performed using the LEGEND MAXTM human α‐synuclein ELISA kit (BioLegend, San Diego, USA). Rho of Spearman correlation coefficients among CSF protein levels were evaluated.Result: CSF α‐syn significantly positively correlated with T‐tau (Rho= 0.41, p=0.17 ) and P‐tau (Rho=0.57, p=0.001) exclusively for MCI‐AD patients. As expected, the tau proteins significantly positively correlated between them in every patient ΄s group and control subjects. No other significant correlations were found.Conclusion: The exclusive correlation between CSF α‐syn and tau protein levels in MCI‐AD patients, support a pathophysiologic connection between the metabolisms of these proteins, even at the early stages of the illness. In our opinion, the role of α‐syn should be included into the new pathogenetic theories of AD.


  • Measurement of CSF α‐synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer’s disease

    by María‐Salud García‐Ayllón, María‐Salud García‐Ayllón, José‐Antonio Monge‐Argilés, José‐Antonio Monge‐Argilés, Victoria Monge‐García, Victoria Monge‐García, Francisco Navarrete, Francisco Navarrete, Maria‐Angeles Cortés‐Gómez, Maria‐Angeles Cortés‐Gómez, et al.

    Previous studies have indicated the potential of cerebrospinal fluid (CSF) α‐synuclein (α‐syn) to be an additional biomarker for improving differential diagnosis of Alzheimer’s disease (AD). We evaluated α‐syn diagnostic performance across a well‐characterized patient cohort with long‐term follow‐up. For this purpose, CSF α‐syn levels were determined in 25 subjects diagnosed with stable mild cognitive impairment (stable MCI; n = 25), 27 MCI cases due to AD (MCI‐AD; n = 32), 24 MCI cases due to Lewy body disease (MCI‐LBD; n = 24) and control subjects (Ctrl; n = 18). CSF α‐syn levels discriminate between the four groups. There were higher α‐syn levels in MCI‐AD patients and lower levels in MCI‐LBD patients. The combination of α‐syn and P‐tau resulted in a specificity of 99% and a sensitivity of 97% for MCI‐AD. MCI‐AD patients with early psychotic symptoms (n = 9) displayed a trend towards a decrease in P‐tau and α‐syn compared to the MCI‐AD patients without psychotic symptoms (n = 23). We conclude that adding CSF α‐syn to central core AD biomarkers improves an early differential diagnosis of MCI‐AD from other forms of MCI.Open Science Badges: This article has received a badge for *Open Materials* because it provided all relevant information to reproduce the study in the manuscript. The complete Open Science Disclosure form for this article can be found at the end of the article. More information about the Open Practices badges can be found at https://cos.io/our-services/open-science-badges/. image


  • Frecuente alteración de la vía amiloide en la demencia con cuerpos de Lewy prodrómica

    by José Antonio Monge Argilés, Victoria Monge García, Ruth Gasparini Berenguer, César García-Pérez Cejuela, Laura Gabaldón Torres, Juan Salas Felipe, Carlos Leiva Santana

    Introduction. Lewy body dementia (LBD) is the most frequent of the degenerative dementias, after Alzheimer's disease. Aim. To analyse the core biomarkers of Alzheimer's disease in the cerebrospinal fluid of exclusively Hispanic patients with prodromal LBD, in order to determine whether there is involvement of the amyloid pathway or the tau pathway. Patients and methods. Between 2008 and 2017 we included 430 patients with mild cognitive impairment according to Petersen criteria, from three hospitals in the province of Alicante. They underwent clinical check-ups every 6-12 months to evaluate their clinical stability or their progression to dementia using current clinical criteria. Among other complementary tests, biomarkers for Alzheimer's disease in the cerebrospinal fluid were analysed. Results. Of all the patients included, 26 developed LBD and 29 remained stable for at least five years, and were thus considered as a reference. In this group only five (17%) had A beta 1-42 protein values below normal, whereas 16 (55%) of the patients with LBD had altered levels. No differences were found in the levels of tau protein. On comparing the LBD groups with and without amyloidosis, differences were only found in the levels of A beta 1-42 protein. Conclusions. We highlight the frequent presence of amyloid pathology in prodromal LBD in our population, and the probable involvement of different metabolic pathways in the same clinically defined dementia.


  • Open Access

    Influence of APOE Genotype on Alzheimer’s Disease CSF Biomarkers in a Spanish Population

    by J. A. Monge-Argilés, R. Gasparini-Berenguer, M. Gutierrez-Agulló, C. Muñoz-Ruiz, J. Sánchez-Payá, C. Leiva-Santana

    Objectives. To evaluate the association between apolipoprotein E (APOE) genotype and cerebrospinal fluid (CSF) levels of Alzheimers disease (AD) biomarkers and to study the influence of APOE genotype on the development of AD in a Spanish population. Material and Methods. The study comprised 29 amnestic mild cognitive impairment (MCI) patients and 27 control subjects. Using ELISA methodology, CSF biomarkers and tau/Aβ ratios were obtained. ANOVA and adjusted odds ratios were calculated. Results. We observed the effect of APOE genotype and age on CSF AD variables. The progression to AD was more clearly influenced by CSF AD variables than by age or APOE status. Conclusions. APOE status influences CSF AD variables. However, the presence of APOE ε4 does not appear to be a deterministic factor for the development of AD, because CSF variables have a greater influence on progression to the disease. These results confirm previous observations and, to our knowledge, are the first published in a Spanish population. Objectives. To evaluate the association between apolipoprotein E (APOE) genotype and cerebrospinal fluid (CSF) levels of Alzheimers disease (AD) biomarkers and to study the influence of APOE genotype on the development of AD in a Spanish population. Material and Methods. The study comprised 29 amnestic mild cognitive impairment (MCI) patients and 27 control subjects. Using ELISA methodology, CSF biomarkers and tau/Aβ ratios were obtained. ANOVA and adjusted odds ratios were calculated. Results. We observed the effect of APOE genotype and age on CSF AD variables. The progression to AD was more clearly influenced by CSF AD variables than by age or APOE status. Conclusions. APOE status influences CSF AD variables. However, the presence of APOE ε4 does not appear to be a deterministic factor for the development of AD, because CSF variables have a greater influence on progression to the disease. These results confirm previous observations and, to our knowledge, are the first published in a Spanish population.